Anivive Lifesciences

"We look forward to our discussions with the FDA and advancing toward a clinical trial, our research over the past few months and our experience with GC376 support the exploration of the drug as an adjunct therapy to standard of care for COVID-19 patients or for patients where standard of care may be contraindicated. Read more: https://www.businesswire.com//Anivive-Repurposes-Veterinar

FDA awards Anivive $500,000 to support the development of Verdinexor. We expect it will become the first targeted canine lymphoma therapy! Read more here: https://www.anivive.com/news/fda-awards-anivive-500k-grant

Does your cat have diabetes? Check out www.AniviveTrial.com/CatDNA to see if your cat qualifies for a free genetic test.